ReviewCellular oncology (Dordrecht, Netherlands)2015
Molecular imaging of targeted therapies with positron emission tomography: the visualization of personalized cancer care.
Review in Cellular oncology (Dordrecht, Netherlands), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Preclinical Evaluation of a Novel PSMA-Targeted AgentTomography (Ann Arbor, Mich.) · 2025Article
- SPECT/CT imaging of EGFR-positive head and neck squamous cell carcinoma patient-derived xenografts withEJNMMI radiopharmacy and chemistry · 2024Article
- Synthesis and Evaluation of [ACS omega · 2024Article
- p53 stabilisation potentiates [European journal of nuclear medicine and molecular imaging · 2024Article
- Application of iron oxide nanoparticles in the diagnosis and treatment of leukemia.Frontiers in pharmacology · 2023Review
- Preclinical Molecular PET-CT Imaging Targeting CDCP1 in Colorectal Cancer.Contrast media & molecular imaging · 2021Article
- Visual and quantitative evaluation of [EJNMMI research · 2020Article
- Pharmacokinetic Modeling of Targeted Ultrasound Contrast Agents for Quantitative Assessment of Anti-Angiogenic Therapy: a Longitudinal Case-Control Study in Colon Cancer.Molecular imaging and biology · 2019Article
- A Distinct Advantage to Intraarterial Delivery ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019Article
- F8-IL10: A New Potential Antirheumatic Drug Evaluated by a PET-Guided Translational Approach.Molecular pharmaceutics · 2019Article
- Selection of Protein Kinase Inhibitors Based on Tumor Tissue Kinase Activity Profiles in Patients with Refractory Solid Malignancies: An Interventional Molecular Profiling Study.The oncologist · 2018Article
- Generalized paired-agent kinetic model for in vivo quantification of cancer cell-surface receptors under receptor saturation conditions.Physics in medicine and biology · 2017Article
- Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLC.EJNMMI research · 2016Article
- First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors.Oncotarget · 2016Article
- DNA nanomaterials for preclinical imaging and drug delivery.Journal of controlled release : official journal of the Controlled Release Society · 2016Review
- Personalized cancer medicine: next steps in the genomic era.Cellular oncology (Dordrecht, Netherlands) · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMolecular imaging has been defined as the visualization, characterization and measurement of biological processes at the molecular and cellular level in humans and other living systems. In oncology it enables to visualize (part of) the functional behaviour of tumour cells, in contrast to anatomical imaging that focuses on the size and location of malignant lesions. Available molecular imaging techniques include single photon emission computed tomography (SPECT), positron emission tomography (PET) and optical imaging. In PET, a radiotracer consisting of a positron emitting radionuclide attached to the biologically active molecule of interest is administrated to the patient. Several approaches have been undertaken to use PET for the improvement of personalized cancer care. For example, a variety of radiolabelled ligands have been investigated for intratumoural target identification and radiolabelled drugs have been developed for direct visualization of the biodistibution in vivo, including intratumoural therapy uptake. First indications of the clinical value of PET for target identification and response prediction in oncology have been reported. This new imaging approach is rapidly developing, but uniformity of scanning processes, standardized methods for outcome evaluation and implementation in daily clinical practice are still in progress. In this review we discuss the available literature on molecular imaging with PET for personalized targeted treatment strategies.
conclusionMolecular imaging with radiolabelled targeted anticancer drugs has great potential for the improvement of personalized cancer care. The non-invasive quantification of drug accumulation in tumours and normal tissues provides understanding of the biodistribution in relation to therapeutic and toxic effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.